---
figid: PMC6319910__nihms-993243-f0002
figlink: /pmc/articles/PMC6319910/figure/F2/
number: Fig. 2
caption: RAS–RAF–MEK–ERK pathway is activated in many types of cancer. Trametinib
  inhibits MEK1/2, blocking the activation of ERK1/2. Dabrafenib and vemurafenib inhibit
  RAF activation.Trametinib and dabrafenib are used in combination to treat BRAF V600
  mutated melanoma
pmcid: PMC6319910
papertitle: 'Cardiovascular Effects of the MEK Inhibitor, Trametinib: A Case Report,
  Literature Review, and Consideration of Mechanism.'
reftext: Mary Banks, et al. Cardiovasc Toxicol. 2017 Oct;17(4):487-493.
pmc_ranked_result_index: '80811'
pathway_score: 0.9667277
filename: nihms-993243-f0002.jpg
figtitle: RAS–RAF–MEK–ERK pathway is activated in many types of cancer
year: '2017'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6319910__nihms-993243-f0002.html
  '@type': Dataset
  description: RAS–RAF–MEK–ERK pathway is activated in many types of cancer. Trametinib
    inhibits MEK1/2, blocking the activation of ERK1/2. Dabrafenib and vemurafenib
    inhibit RAF activation.Trametinib and dabrafenib are used in combination to treat
    BRAF V600 mutated melanoma
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - MAPK3
  - MAP2K2
  - MAP2K1
  - MAPK1
  - KRAS
  - NRAS
  - HRAS
  - BRAF
  - RAF1
  - ARAF
  - trametinib
  - dabrafenib
  - tyrosine
  - Cancer
  - Cardiomyopathy
  - Noonan syndrome
genes:
- word: ERK1/2
  symbol: ERK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: MEK1/2
  symbol: MEK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: ERK1/2
  symbol: ERK2
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: MEK1/2
  symbol: MEK2
  source: hgnc_alias_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: (BRAF
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
chemicals:
- word: trametinib
  source: MESH
  identifier: C560077
- word: dabrafenib
  source: MESH
  identifier: C561627
- word: tyrosine
  source: MESH
  identifier: D014443
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
---
